Previous 10 | Next 10 |
Curaleaf (CURA CN) initiated with Neutral rating and C$11.40 (41% upside) price target at Cantor Fitzgerald. U.S. ticker: ( OTCPK:CURLF ). More news on: Curaleaf Holdings, Inc., Pfenex Inc., Trulieve Cannabis Corp., Healthcare stocks news, Stocks on the move, , Read more ...
Listen on the go! A daily podcast of Wall Street Breakfast will be available by 8:00 a.m. on Seeking Alpha , iTunes , Stitcher and Spotify (click the highlighted links). Nasdaq futures increased 0.27% , S&P futures inched up 0.14% and Dow futures are basically fl...
Pulse Biosciences (NASDAQ: PLSE ) -25.2% after-hours following the disclosure of a "Not Substantially Equivalent" letter from the Food and Drug Administration related to its CellFX system. More news on: Pulse Biosciences, Inc., Healthcare stocks news, Stocks on the move, Read more .....
Schedules Business Update Call on February 18, 2020 at 2:00pm PT Pulse Biosciences, Inc. (Nasdaq: PLSE), a novel bioelectric medicine company, today announced an update on its U.S. Food and Drug Administration (FDA) submission for the CellFX System. Previously, the Company submitted a ...
Pulse Biosciences, Inc. (Nasdaq: PLSE) (the “Company”), a novel bioelectric medicine company, today announced the presentation of its scientific study evaluating the clinical and histologic response of Nano-Pulse Stimulation™ (NPS™) technology in treating challengi...
Editor's note: Seeking Alpha is proud to welcome Marvl Research as a new contributor. It's easy to become a Seeking Alpha contributor and earn money for your best investment ideas. Active contributors also get free access to SA PREMIUM. Click here to find out more » CellFX, a Pulse Bi...
Pulse Biosciences, Inc. (Nasdaq: PLSE) (the “Company), a novel bioelectric medicine company bringing to market its proprietary CellFX™ System, today announced an update to its regulatory timeline with the Food and Drug Administration (FDA). In connection with the ongoing review ...
Pulse Biosciences, Inc. (PLSE) Q3 2019 Earnings Conference Call November 7, 2019 16:30 ET Company Participants Brian Dow - SVP & CFO Darrin Uecker - President & CEO Ed Ebbers - EVP & GM, Dermatology Conference Call Participants Arthur He - H.C. Wainwright Pre...
Image source: The Motley Fool. Pulse Biosciences, Inc Common Stock (NASDAQ: PLSE) Q3 2019 Earnings Call Nov 07, 2019 , 4:30 p.m. ET Operator Continue reading
Pulse Biosciences (NASDAQ: PLSE ): Q3 Non-GAAP EPS of -$0.57 beats by $0.04 . Cash and cash equivalents of $9.57M. Shares -2.5% Press Release More news on: Pulse Biosciences, Inc., Earnings news and commentary, Healthcare stocks news,
News, Short Squeeze, Breakout and More Instantly...
Pulse Biosciences Inc Company Name:
PLSE Stock Symbol:
NASDAQ Market:
Pulse Biosciences Inc Website:
Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation™ (nsPFA™) technology, today announced it will report financial results for the second quarter 2024 after market close on Monday, August 12, 2024. Company managemen...
2024-07-15 17:56:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
A look at the top 10 most actives in the United States Maxeon Solar Technologies Ltd. (MAXN) rose 12.5% to $0.27 on volume of 477,193,667 shares NVIDIA Corporation (NVDA) rose 1.9% to $128.2 on volume of 232,119,115 shares Virpax Pharmaceuticals Inc. (VRPX) rose 92.0% to $1.11 on volume o...